Novel Applications of 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol Compounds in Veterinary Medicine

This inventive concept explores the use of 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds in novel veterinary applications, leveraging their CDK inhibitory properties to address unmet needs in animal health.

The original patent disclosed 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors for human cancer treatment. However, there is a significant need for effective treatments for neurological disorders, anxiety, and cognitive decline in companion animals. This inventive concept addresses these unmet needs by applying the core technology to veterinary medicine.

The new claims describe systems, methods, and compositions for treating neurological disorders, reducing anxiety, and improving cognitive function in animals using 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds. These inventions encompass various delivery mechanisms, nutritional supplements, and diagnostic tools tailored to the specific needs of veterinary medicine.

The novelty of this inventive concept lies in the unexpected application of 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds to veterinary medicine, which is not obvious from the original patent's focus on human cancer treatment.

Alternative embodiments may include different formulations, dosing regimens, and administration routes for the compounds, as well as integration with existing veterinary diagnostic tools and treatments.

The inventive concept has significant commercial potential in the veterinary pharmaceutical industry, with a growing market demand for effective treatments for animal health and wellness.